Clinical Trial Update: The INFECIR-2 Albumin Prevention Study [Phase 4]

View source ↗

Summary

The INFECIR-2 Albumin Prevention Study is a Phase 4 trial sponsored by the EASL-CLIF Consortium. It has been terminated; no results are provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Cholangitis
• Liver Disease
• Pneumonia
• Urinary Tract Infection

Snippet

Sponsor: EASL - CLIF Consortium | Conditions: Advanced Chronic Liver Disease, Urinary Infection | Phase 4 | Status: TERMINATED